Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

To evaluate the efficacy and safety of RC148 plus platinum-based chemotherapy versus tislelizumab plus platinum-based chemotherapy in trial participants with previously untreated locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV), non-squamous non-small cell lung cancer without actionable genomic alterations.

Trial Details

NCT ID
NCT07829549
Phase
PHASE3
Sponsor
RemeGen Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection
  • Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection
Locations (sample)
  • Hunan, Changsha, China|32.92741,120.18021

Key Eligibility Criteria

  • 1\. Voluntarily agrees to participate in the study and provides written informed consent.
  • 2\. Willing and able to comply with study and follow-up procedures. 3. Male or female, aged 18 to 75 years inclusive. 4. Estimated life expectancy≥…
  • 7\. No prior systemic anti-tumor therapy for advanced or metastatic NSCLC 8. Has at least one measurable non-central nervous system lesion per RECI…
  • 9\. Must provide PD-L1 expression testing report and actionable genomic alterations testing report before enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →